mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs

被引:550
作者
Dowling, Ryan J. O. [1 ,2 ]
Topisirovic, Ivan [1 ,2 ]
Alain, Tommy [1 ,2 ]
Bidinosti, Michael [1 ,2 ]
Fonseca, Bruno D. [1 ,2 ]
Petroulakis, Emmanuel [1 ,2 ]
Wang, Xiaoshan [1 ,2 ]
Larsson, Ola [1 ,2 ]
Selvaraj, Anand [3 ]
Liu, Yi [4 ]
Kozma, Sara C. [3 ]
Thomas, George [3 ]
Sonenberg, Nahum [1 ,2 ]
机构
[1] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada
[2] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada
[3] Univ Cincinnati, Dept Canc & Cell Biol, Metab Dis Inst, Cincinnati, OH 45237 USA
[4] Intellikine, La Jolla, CA 92037 USA
基金
加拿大健康研究院; 加拿大自然科学与工程研究理事会;
关键词
INSULIN-RESISTANCE; CANCER-THERAPY; MTOR; INHIBITOR; PHOSPHORYLATION; DOWNSTREAM; DROSOPHILA; REGULATOR; PROTEINS; KINASE;
D O I
10.1126/science.1187532
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The mammalian target of rapamycin complex 1 (mTORC1) integrates mitogen and nutrient signals to control cell proliferation and cell size. Hence, mTORC1 is implicated in a large number of human diseases-including diabetes, obesity, heart disease, and cancer-that are characterized by aberrant cell growth and proliferation. Although eukaryotic translation initiation factor 4E-binding proteins (4E-BPs) are critical mediators of mTORC1 function, their precise contribution to mTORC1 signaling and the mechanisms by which they mediate mTORC1 function have remained unclear. We inhibited the mTORC1 pathway in cells lacking 4E-BPs and analyzed the effects on cell size, cell proliferation, and cell cycle progression. Although the 4E-BPs had no effect on cell size, they inhibited cell proliferation by selectively inhibiting the translation of messenger RNAs that encode proliferation-promoting proteins and proteins involved in cell cycle progression. Thus, control of cell size and cell cycle progression appear to be independent in mammalian cells, whereas in lower eukaryotes, 4E-BPs influence both cell growth and proliferation.
引用
收藏
页码:1172 / 1176
页数:5
相关论文
共 26 条
  • [1] Not all substrates are treated equally Implications for mTOR, rapamycin-resistance and cancer therapy
    Choo, Andrew Y.
    Blenis, John
    [J]. CELL CYCLE, 2009, 8 (04) : 567 - 572
  • [2] Conlon Ian, 2003, J Biol, V2, P7, DOI 10.1186/1475-4924-2-7
  • [3] eIF-4E expression and its role in malignancies and metastases
    De Benedetti, A
    Graff, JR
    [J]. ONCOGENE, 2004, 23 (18) : 3189 - 3199
  • [4] Identification of a novel inhibitor of mitogen-activated protein kinase kinase
    Favata, MF
    Horiuchi, KY
    Manos, EJ
    Daulerio, AJ
    Stradley, DA
    Feeser, WS
    Van Dyk, DE
    Pitts, WJ
    Earl, RA
    Hobbs, F
    Copeland, RA
    Magolda, RL
    Scherle, PA
    Trzaskos, JM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (29) : 18623 - 18632
  • [5] Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
    Feldman, Morris E.
    Apsel, Beth
    Uotila, Aino
    Loewith, Robbie
    Knight, Zachary A.
    Ruggero, Davide
    Shokat, Kevan M.
    [J]. PLOS BIOLOGY, 2009, 7 (02) : 371 - 383
  • [6] Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
    Garcia-Martinez, Juan M.
    Moran, Jennifer
    Clarke, Rosemary G.
    Gray, Alex
    Cosulich, Sabina C.
    Chresta, Christine M.
    Alessi, Dario R.
    [J]. BIOCHEMICAL JOURNAL, 2009, 421 : 29 - 42
  • [7] Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism
    Gingras, AC
    Gygi, SP
    Raught, B
    Polakiewicz, RD
    Abraham, RT
    Hoekstra, MF
    Aebersold, R
    Sonenberg, N
    [J]. GENES & DEVELOPMENT, 1999, 13 (11) : 1422 - 1437
  • [8] Targeting the eukaryotic translation initiation factor 4E for cancer therapy
    Graff, Jeremy R.
    Konicek, Bruce W.
    Carter, Julia H.
    Marcusson, Eric G.
    [J]. CANCER RESEARCH, 2008, 68 (03) : 631 - 634
  • [9] Defining the role of mTOR in cancer
    Guertin, David A.
    Sabatini, David M.
    [J]. CANCER CELL, 2007, 12 (01) : 9 - 22
  • [10] Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action
    Hara, K
    Maruki, Y
    Long, XM
    Yoshino, K
    Oshiro, N
    Hidayat, S
    Tokunaga, C
    Avruch, J
    Yonezawa, K
    [J]. CELL, 2002, 110 (02) : 177 - 189